Regen-cov And Ronapreve Market Report 2026

Regen-cov And Ronapreve Market Overview

• The Regen-cov And Ronapreve market growth in the historic period has been driven by global spread of covid-19 infections, emergency authorization of antibody therapies • Market expansion is supported by increasing focus on pandemic preparedness, rising demand for rapid-response biologics • Growth Driver: Rising Incidence Of Infectious Diseases To Drive Growth In The Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Regen-cov And Ronapreve Market?

Regen-cov and ronapreve are monoclonal antibody therapy combining casirivimab and imdevimab, designed to neutralize SARS-CoV-2 by targeting its spike protein, preventing cell entry. It is authorized for treating mild-to-moderate COVID-19 in high-risk patients and as post-exposure prophylaxis, reducing hospitalization and death rates effectively. The main types of clinical indications in regen-cov and ronapreve are treatment of mild to moderate COVID-19, post-exposure prophylaxis (PEP), and pre-exposure prophylaxis (PrEP). Treatment of mild to moderate COVID-19 refers to the therapeutic use of medications for patients diagnosed with COVID-19 who are experiencing mild to moderate symptoms and are not hospitalized. It is distributed through hospitals, outpatient clinics, and home healthcare for various end users, including pediatric, adult, and geriatric.

What Is The Regen-cov And Ronapreve Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising demand for rapid-response biologics, expansion of outpatient infusion services, growing investment in monoclonal antibody platforms, increasing development of variant-specific therapies. Major trends in the forecast period include increasing deployment of monoclonal antibody therapies, rising use of passive immunization treatments, growing focus on early viral neutralization, expansion of emergency use biologics, enhanced integration of pandemic response therapies.

Global Regen-cov And Ronapreve Market Segmentation

1) By Clinical Indication: Treatment Of Mild To Moderate COVID-19, Post-Exposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP) 2) By Distribution Channel: Hospitals, Outpatient Clinics, Home Healthcare 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Regen-cov And Ronapreve Market?

Rising incidence of infectious diseases is expected to propel growth of the regen-cov and ronapreve market going forward. Infectious diseases are illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, which spread through contact, air, water, or contaminated food. The rising incidence of infectious diseases is fueled by climate change, which expands the range of vectors like mosquitoes, and globalization, where increased travel rapidly spreads pathogens across borders. Regen-Cov (Ronapreve) is a monoclonal antibody cocktail used to treat COVID-19, targeting the SARS-CoV-2 virus to prevent severe illness, particularly in high-risk patients. For instance, in November 2024, according to the National Library of Medicine (NLM), a US-based government agency, between 5 and 11 November, 167,369 people in England tested positive for COVID-19, marking an 11% increase from the previous week. The positivity rate remained steady at 9.6%, close to the 9.7% reported the week before. Therefore, the rising incidence of infectious diseases is driving the growth of the regen-cov and ronapreve industry. The rising healthcare investments are expected to propel the growth of the regen-cov and ronapreve market going forward. Healthcare investments refer to the allocation of capital into the healthcare sector, including funding for medical technologies, pharmaceuticals, healthcare facilities, and services. Healthcare investments are rising due to the aging population, which increases demand for healthcare services, and advancements in medical technology, which drive innovation and improve patient care. Healthcare investments are used for regen-cov and ronapreve to fund clinical trials, expand production, secure regulatory approvals, and enhance distribution to ensure wider accessibility and adoption of the treatment. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental organization, reported that in 2024, average health spending in OECD countries was estimated to stand at nearly USD 6 000 per capita (when adjusted for differences in purchasing power). Therefore, the rising healthcare investments are driving the growth of the regen-cov and ronapreve industry. The rising prevalence of chronic diseases is expected to propel the growth of the Regen-cov And Ronapreve market going forward. Chronic diseases are long-lasting medical conditions that persist for a year or more, often requiring ongoing management and care, such as diabetes, heart disease, and asthma. The growing incidence of chronic diseases is driven by factors such as aging populations, unhealthy lifestyles (including poor diet and lack of exercise), and increased prevalence of risk factors like obesity, diabetes, and hypertension. Regen-COV and Ronapreve support chronic disease patients by reducing the risk of severe COVID-19 complications, providing targeted antibody protection for individuals with weakened immune responses. For instance, in July 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australia based government health statistics agency, chronic conditions accounted for 78% of fatal burden, up from previous years. Therefore, the rising prevalence of chronic diseases is driving the growth of the Regen-cov And Ronapreve industry.

Key Players In The Global Regen-cov And Ronapreve Market

Major companies operating in the regen-cov and ronapreve market are F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals

Regional Insights

North America was the largest region in the regen-cov and ronapreve market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Regen-cov And Ronapreve Market?

The regen-cov and ronapreve market consists of sales of monoclonal antibodies, intravenous (IV) infusion solutions, and subcutaneous (SubQ) injection solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Regen-cov And Ronapreve Market Report 2026?

The regen-cov and ronapreve market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the regen-cov and ronapreve industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.